Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Immune checkpoint blockade targeting programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) shows promise for cancer immunotherapy.
• Effective delivery and tumor penetration of therapeutic agents remain challenges in cancer treatment.

Purpose of the Study:

• To develop ultrasensitive pH-triggered nanoparticles loaded with shPD-L1 for effective PD-L1 gene silencing.
• To enhance nanoparticle tumor penetration using hyaluronidase (HAase) for improved cancer therapy.

Main Methods:

• Plasmid DNA encoding shPD-L1 was encapsulated in pH-triggered P[(GP)D] nanoparticles.
• Hyaluronidase was used to degrade hyaluronic acid in the tumor extracellular matrix, facilitating nanoparticle penetration.
• In vivo antitumor efficacy was evaluated in a murine melanoma model.

Main Results:

• The P[(GP)D] nanoparticles demonstrated pH-triggered release and enhanced tumor accumulation and penetration when combined with HAase.
• Combination treatment with HAase and shPD-L1-loaded nanoparticles resulted in significant tumor inhibition.
• Effective PD-L1 gene silencing and potent tumor suppression were achieved.

Conclusions:

• HAase-mediated degradation of tumor hyaluronic acid effectively enhances nanoparticle penetration and therapeutic efficacy.
• This combination strategy offers a promising approach for improving nanomedicine delivery and cancer treatment.
• The developed system has broad potential applications in future cancer therapies.